

Intensity (counts)
10,000
8000
6000
4000
2000
0
5
10
15
20
25
30
35
2 Theta (°)

FIG. 1



Heat Flow (W/g)
2
0
-2
-4
-6
-8
Weight (%)
102
100
98
96
94
92
90
Exo Up
0
50
100
150
200
250
300
350
Temperature (°C)
negligible wt loss by TGA prior to thermal decomposition
174.98°C
85.63J/g
177.65°C

FIG. 2



Intensity (counts)
7000
6000
5000
4000
3000
2000
1000
0
5
10
15
20
25
30
35
2 Theta (°)

FIG. 3



Weight (%)
106.0
105.5
105.0
104.5
104.0
103.5
103.0
102.5
102.0
101.5
101.0
100.5
100.0
99.5
99.0
Heat Flow (W/g)
3
1
-1
-3
-5
Exo Up
0
50
100
150
200
250
Temperature (°C)
167.41°C
170.15°C
1.064% wt loss to 220C
Wt loss due to MTBE + minor CO2 evolution

FIG. 4

FIG. 5A



Final dose 3h prior to IgG challenge
Extravasation diameter mm
0
2
4
6
8
10
12
Gel Vehicle level
Betamethasone level
**
**
**
**
Gel Vehicle
Betamethasone
2% Compound (I)
1% Compound (I)
0.5% Compound (I)
0.25% Compound (I)

FIG. 5B



Final dose 3h prior to IgG challenge
OD620 reading
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
Gel Vehicle level
Betamethasone level
**
**
**
*
Gel Vehicle
Betamethasone
2% Compound (I)
1% Compound (I)
0.5% Compound (I)
0.25% Compound (I)

FIG. 6A



Extravasation diameter mm
14
12
10
8
6
4
2
0
Ointment Vehicle level
Betamethasone level
Ointment Vehicle
Betamethasone
2% Compound (I)
1% Compound (I)
0.5% Compound (I)
0.25% Compound (I)

FIG. 6B



OD570 reading
1.6
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
Ointment Vehicle level
Betamethasone level
Ointment Vehicle
Betamethasone
2% Compound (I)
1% Compound (I)
0.5% Compound (I)
0.25% Compound (I)

FIG. 7A




Extravasation diameter mm
0
2
4
6
8
10
12
Ointment Vehicle level
Betamethasone level
Ointment Vehicle
Betamethasone
2% Compound (I)
1% Compound (I)
0.5% Compound (I)
0.25% Compound (I)

FIG. 7B


OD_{450} reading
0.6
0.8
1.0
1.2
1.4
1.6
1.8
Ointment Vehicle level
Betamethasone level
Ointment Vehicle
Betamethasone
2% Compound (I)
1% Compound (I)
0.5% Compound (I)
0.25% Compound (I)



Epidermis
Dermis
Mean Amount Drug Recovered (ng)
4000
3000
2000
1000
0
2% (Crystalline Form (II))
2% (Amorphous)
2% (Crystalline Form (III))
Compound (I) Gel Formulation

FIG. 8